<DOC>
	<DOC>NCT02852395</DOC>
	<brief_summary>This is a 3-part study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of JNJ-48816274 in healthy participants after administration of single and repeated doses, and to evaluate its potential effectiveness for treating insomnia.</brief_summary>
	<brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-48816274</brief_title>
	<detailed_description />
	<criteria>Must be healthy as assessed by medical history and safety evaluations performed at screening Has a body mass index between 18 and 30 kilogram per square meter (kg/m2) and body weight not less than 50 kg Must be willing and able to abide by the prohibitions and restrictions of the study, including requirements for contraception Women must not be of childbearing potential by either being postmenapausal or permanently sterilized Part 2 Only: Maintains a regular sleepwake cycle as measured by sleep diaries and a watch that measures activity Has a habitual (majority of days) bedtime and duration of sleep that meet the study requirements Current or history of clinically significant medical or psychiatric illness, or recent major surgery or blood loss/donation Any current sleepwake disorder, recent night shift work, or history of insomnia within the last 5 years Man who has a pregnant female partner Woman who is breastfeeding Is participating or has participated within the last 3 months in a study with an investigational drug or medical device Tests positive or has a history of human immunodeficiency virus (HIV), hepatitis B, hepatitis C, or other active liver disease Drug or alcohol abuse within the last 5 years, nicotine use within the last 3 months, or tests positive for alcohol, drugs of abuse, or nicotine Routinely consumes an excessive amount of caffeine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>